UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: the iron overload syndromes

Alimentary pharmacology & therapeutics, 2012-04, Vol.35 (8), p.876-893

2012

Volltextzugriff (PDF)

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

The New England journal of medicine, 2010-05, Vol.362 (18), p.1675-1685

2010

Volltextzugriff (PDF)

Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis

Alimentary pharmacology & therapeutics, 2013-07, Vol.38 (2), p.134-143

2013

Volltextzugriff (PDF)

High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

Alimentary pharmacology & therapeutics, 2011-11, Vol.34 (10), p.1185-1192

2011

Volltextzugriff (PDF)

Editorial: frequency of surveillance and survival in hepatocellular carcinoma

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (2), p.228-229

2018

Volltextzugriff (PDF)

Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study

Journal of viral hepatitis, 2017-01, Vol.24 (1), p.22-27

2017

Volltextzugriff (PDF)

Hepatitis C virus re‐treatment in the era of direct‐acting antivirals: projections in the USA

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (7), p.1023-1031

2018

Volltextzugriff (PDF)

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Alimentary pharmacology & therapeutics, 2017-09, Vol.46 (5), p.540-548

2017

Volltextzugriff (PDF)

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

Annals of internal medicine, 2001-01, Vol.134 (2), p.89

2001

Volltextzugriff (PDF)

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network

Journal of viral hepatitis, 2016-06, Vol.23 (6), p.447-454

2016

Volltextzugriff (PDF)

Editorial: improved understanding of the epidemiology of primary biliary cirrhosis in South Korea

Alimentary pharmacology & therapeutics, 2016-03, Vol.43 (5), p.650-651

2016

Volltextzugriff (PDF)

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

Gastroenterology (New York, N.Y. 1943), 2004-01, Vol.126 (1), p.91-101

2004

Volltextzugriff (PDF)

Increased parenchymal damage and steatohepatitis in Caucasian non‐alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms

Alimentary pharmacology & therapeutics, 2016-12, Vol.44 (11-12), p.1253-1264

2016

Volltextzugriff (PDF)

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2015-05, Vol.41 (10), p.980-990

2015

Volltextzugriff (PDF)

Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network

Journal of hepatology, 2017, Vol.66 (1), p.S726-S726

2017

Volltextzugriff (PDF)

Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network

Journal of hepatology, 2017, Vol.66 (1), p.S58-S58

2017

Volltextzugriff (PDF)

Real-world treatment utilization and results in the renaissance of HCV Care: analyses of treatment for 7,550 Patients from the TRIO Network

Journal of hepatology, 2017, Vol.66 (1), p.S740-S741

2017

Volltextzugriff (PDF)

Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network

Journal of hepatology, 2017, Vol.66 (1), p.S748-S749

2017

Volltextzugriff (PDF)

Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO Network

Journal of hepatology, 2017, Vol.66 (1), p.S295-S295

2017

Volltextzugriff (PDF)

Ursodeoxycholic acid therapy in hepatobiliary disease

The American Journal of Medicine, 2000-04, Vol.108 (6), p.481-486

Kowdley, Kris V

2000

Volltextzugriff (PDF)

All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3

Journal of hepatology, 2016, Vol.64 (2), p.S789-S790

2016

Volltextzugriff (PDF)

Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension

Alimentary pharmacology & therapeutics, 2012-04, Vol.35 (8), p.904-912

2012

Volltextzugriff (PDF)

Ledipasvir/Sofosbuvir+/−Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the Trio Network

Journal of hepatology, 2016, Vol.64 (2), p.S756-S757

2016

Volltextzugriff (PDF)

Ledipasvir/Sofosbuvir ± Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the Trio Network

Journal of hepatology, 2016, Vol.64 (2), p.S822-S823

2016

Volltextzugriff (PDF)

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network

Journal of hepatology, 2016, Vol.64 (2), p.S222-S222

2016

Volltextzugriff (PDF)

1 – 25 von 405

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(394)
Mit Volltextzugriff
(328)

Publikationsform

Sprache

Englisch
(405)

Erscheinungsjahr

n.n

Thema

Humans
(216)
Life Sciences & Biomedicine
(211)
Science & Technology
(211)
Gastroenterology & Hepatology
(149)
Male
(117)
Female
(116)
Middle Aged
(104)
Adult
(96)
Biological And Medical Sciences
(94)
Medical Sciences
(92)
Gastroenterology And Hepatology
(76)
Aged
(60)
Gastroenterology. Liver. Pancreas. Abdomen
(42)
General & Internal Medicine
(32)
Medicine, General & Internal
(32)
Treatment Outcome
(32)
Adolescent
(30)
Genotype
(29)
Liver. Biliary Tract. Portal Circulation. Exocrine Pancreas
(29)
Other Diseases. Semiology
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Review article: the iron overload syndromes

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis

High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

Editorial: frequency of surveillance and survival in hepatocellular carcinoma

Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study

Hepatitis C virus re‐treatment in the era of direct‐acting antivirals: projections in the USA

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network

Editorial: improved understanding of the epidemiology of primary biliary cirrhosis in South Korea

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

Increased parenchymal damage and steatohepatitis in Caucasian non‐alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease

Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network

Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network

Real-world treatment utilization and results in the renaissance of HCV Care: analyses of treatment for 7,550 Patients from the TRIO Network

Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network

Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO Network

Ursodeoxycholic acid therapy in hepatobiliary disease

All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3

Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension

Ledipasvir/Sofosbuvir+/−Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the Trio Network

Ledipasvir/Sofosbuvir ± Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the Trio Network

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network

Suchergebnisse filtern